40843-55-8Relevant articles and documents
Method for selectively preparing hydroquinone monoether compound or quinol compound (by machine translation)
-
Paragraph 0034-0039; 0050-0052; 0089-0090, (2020/12/30)
The method comprises the following steps: taking an organic boric acid compound and a p-benzoquinone compound as a reaction raw material, under the action of a copper catalyst, selectively reacting to obtain a hydroquinone monoether compound or a quinol compound. Compared with the prior art, the method disclosed by the invention adopts a one-pot reaction, can selectively obtain two products through solvent control, is suitable for preparing various types of hydroquinone monoether compounds and quinol compounds, and has wide applicability. The substrate functional group is high in tolerance and wide in substrate range. The raw material and the catalyst are cheap and easily available, the reaction conditions are mild, the reaction solvent is green and environment-friendly, the post-treatment is simple, and the yield and purity of the product are high. The preparation method is convenient. The method is rapid and efficient, and has a good application prospect in drug molecule synthesis. (by machine translation)
BIARYL SUBSTITUTED NITROGEN CONTAINING HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION
-
Page/Page column 10, (2008/06/13)
The present invention relates to a chemical genus of biaryl substituted nitrogen-attached heterocycles that are inhibitors of LTA4H (leukotriene A4 hydrolase). The compounds have the general formula: They are useful for the treatment and prevention and pr
5-Aryl thiazolidine-2,4-diones as selective PPARγ agonists
Koyama, Hiroo,Boueres, Julia K.,Han, Wei,Metzger, Edward J.,Bergman, Jeffrey P.,Gratale, Dominick F.,Miller, Daniel J.,Tolman, Richard L.,MacNaul, Karen L.,Berger, Joel P.,Doebber, Thomas W.,Leung, Kwan,Moller, David E.,Heck, James V.,Sahoo, Soumya P.
, p. 1801 - 1804 (2007/10/03)
A series of 5-aryl thiazolidine-2,4-diones containing 4-phenoxyphenyl side chains was designed, synthesized, and evaluated for PPAR agonist activities. One such compound 28 exhibited comparable levels of glucose correction to rosiglitazone in the db/db mouse type 2 diabetes animal model.